Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRC
June 12th 2019Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.
Read More
Dr. Lenz on Potential for Immunotherapy in mCRC
December 20th 2018Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.
Read More
Dr. Lenz on the Benefit of Regorafenib in CRC
October 26th 2018Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).
Read More
Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC
October 16th 2018Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).
Read More
Dr. Lenz on the Changing Landscape of Metastatic Colorectal Cancer
October 16th 2018Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).
Read More
Dr. Lenz Describes Excitement Over Advances in GI Cancer
August 16th 2013Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.
Read More